Multivalent Targeted Theranostic Liposomes for Chemo-resistant Aggressive CaP
Technical Report,17 Aug 2015,16 Aug 2016
Washington State University Pullman United States
Pagination or Media Count:
While diagnosis and treatment methods of prostate cancer CaP continue to improve, drug resistance pathways in advance stage disease still requires new methodologies to better identify, and treat CaP with fewer side effects for patients. The research objective was to develop new theranostic Thx liposomes capable of independently targeting three protein receptors expressed at different stages of advanced PCa cells for delivery of imaging and therapeutic components in a single package. The multi-valent liposomes were loaded with a therapeutic docetaxel and PIM1 inhibitor SGI-1776 to resensitize docetaxel resistant cells. This approach was examined to provide a targeted delivery of encapsulated therapeutics in comparison to systemic delivery methods in vitro.
- Medicine and Medical Research